title: [Antipsychotics in depression].
abstract: Depression is a major public health problem. In the treatment of depression, the main objectives must be complete remission and prevention of recurrence. However, the objective of remission remains difficult in clinical practice. Several pharmacological strategies exist to handle treatment resistant depression and achieve remission. Among these options, addition of an atypical antipsychotic has become a popular choice. Second generation antipsychotics have been investigated in clinical trials in treatment resistant depression and in bipolar depression. Scientific data are available particularly for aripiprazole and quetiapine XR.
authors.affiliation: Service de Psychiatrie, CHU de Liège, Belgique. wpitchot@chu.ulg.ac.be
authors.forename: W
authors.initials: W
authors.lastname: Pitchot
authors.forename: G
authors.initials: G
authors.lastname: Scantamburlo
authors.forename: D
authors.initials: D
authors.lastname: Souery
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000503:physiopathology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004351:Drug Resistance; D006801:Humans; D012074:Remission Induction / Q000379:methods; D055502:Secondary Prevention
chemical_list: D014150:Antipsychotic Agents